Calquence (acalabrutinib tablets) — Cigna
Marginal Zone Lymphoma
Initial criteria
- Patient age ≥ 18 years
- Patient has tried at least one systemic regimen [examples include bendamustine, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, lenalidomide, or chlorambucil]
Approval duration
1 year